Abstract
The target proteasome has been the focus of drug discovery since the first drug bortezomib was launched in 2003. Many structurally diverse proteasome inhibitors were discovered and even some of them entered the clinical trials. Due to rapid technological progress in chemistry, bioinformatics, structural biology and computer technology, computeraided drug design (CADD) plays a more and more important role in todays drug discovery. Many CADD technologies were employed in designing various inhibitors of proteasome in the past years. This review gives a global description of the development of computer-aided proteasome inhibitor design by using different commercial or academic software. The binding modes of some structurally novel inhibitors with proteasome were visualized with these new technologies.
Keywords: Proteasome inhibitor, Computer-aided drug design, Rational drug design, biological targets, polyubiquitin chains, constitutive proteasome, drug discovery, N-terminal threonine, nucleophilic attack, amide compounds, biologically evaluated, CH hydrogen and electron system, hydrogen bonds, ubiquitin-proteasome pathway
Current Topics in Medicinal Chemistry
Title: Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Volume: 11 Issue: 23
Author(s): Meng Lei, Yunde Liu, Yongqiang Zhu and Zhenming Liu
Affiliation:
Keywords: Proteasome inhibitor, Computer-aided drug design, Rational drug design, biological targets, polyubiquitin chains, constitutive proteasome, drug discovery, N-terminal threonine, nucleophilic attack, amide compounds, biologically evaluated, CH hydrogen and electron system, hydrogen bonds, ubiquitin-proteasome pathway
Abstract: The target proteasome has been the focus of drug discovery since the first drug bortezomib was launched in 2003. Many structurally diverse proteasome inhibitors were discovered and even some of them entered the clinical trials. Due to rapid technological progress in chemistry, bioinformatics, structural biology and computer technology, computeraided drug design (CADD) plays a more and more important role in todays drug discovery. Many CADD technologies were employed in designing various inhibitors of proteasome in the past years. This review gives a global description of the development of computer-aided proteasome inhibitor design by using different commercial or academic software. The binding modes of some structurally novel inhibitors with proteasome were visualized with these new technologies.
Export Options
About this article
Cite this article as:
Lei Meng, Liu Yunde, Zhu Yongqiang and Liu Zhenming, Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors, Current Topics in Medicinal Chemistry 2011; 11 (23) . https://dx.doi.org/10.2174/156802611798281366
DOI https://dx.doi.org/10.2174/156802611798281366 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Functional Genomics Approaches in Cancer Research
Current Genomics Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Unravelling the Power of Omics for the Infertile Aging Male
Current Pharmaceutical Design Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry